Sveriges mest populära poddar
GEN Podcasts
VetenskapLife Science

Looking at the CAR-T Landscape As First Approval Nears

4 min•19 juli 2017
GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.

Hosted on Acast. See acast.com/privacy for more information.

Fler avsnitt av GEN Podcasts

Visa alla avsnitt av GEN Podcasts
Emerging Markets Collaborate to Succeed in Post-Pandemic World
•19 min
Breathing Oxygen Back into the Biological Conversation
•19 min
Global Single-Use Network Supports Assurance of Supply
•27 min
Resins Address Downstream Purification Concerns
•20 min
Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies
•21 min
Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development
•23 min
Moving the Drug Pipeline Forward with Mechanistic Modeling
•26 min
Reducing Drug Discovery and Development Risk with Mechanistic Modeling
•40 min
Meet the Editor-in-Chief of GEN Biotechnology: Hana El-Samad, PhD
•43 min
Interrogating the Links between Genetics and Psychiatric Disorders with High Throughput Assays
•29 min

GEN Podcasts med Genetic Engineering and Biotechnology News finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.